MAPT and Alzheimer disease: This was also true for the clinical diagnosis, possibly due to the presence of preclinical AD in the aDS group, as supported by substantially higher p-tau217 levels in asymptomatic Aβ+ individuals in the DS compared to the euploid group and the aforementioned higher amyloid and tau burden in DS28,29.